Bad news for Orexigen (OREX -38%) and its Contrave obesity drug: Regulators "requested a...

|About: Orexigen Therapeutics, Inc. (OREX)|By:, SA News Editor

Bad news for Orexigen (OREX -38%) and its Contrave obesity drug: Regulators "requested a pre-approval cardiovascular outcomes trial that OREX believes is unprecedented and would generate significantly more information than is necessary or feasible." Regulators also won't consider approving Contrave for a narrowed population without first reviewing data from the trial. (PR)